Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Laboratory_Services
|
| gptkbp:clinical_trial |
Phase I Trials
Phase II Trials Phase III Trials |
| gptkbp:collaborates_with |
Academic Institutions
|
| gptkbp:employs |
gptkb:scientists
gptkb:researchers Pharmacologists Clinical Trial Managers |
| gptkbp:focuses_on |
Pharmaceutical Research
|
| gptkbp:founded_by |
gptkb:Eli_Lilly
|
| gptkbp:funding |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:has_awards |
Innovation Awards
Research Excellence Awards |
| gptkbp:has_collaborations_with |
Government Agencies
Non-Profit Organizations Biotech Companies |
| gptkbp:has_goal |
Improve Patient Outcomes
Enhance Drug Efficacy Reduce Drug Development Time Develop New Therapies Increase Research Collaboration |
| gptkbp:has_part |
Research Teams
Laboratory Facilities Clinical Research Units |
| gptkbp:has_publications |
Research Papers
Scientific Journals Clinical Studies |
| gptkbp:has_research_areas |
gptkb:diabetes
gptkb:Oncology Immunology Neuroscience Cardiovascular Diseases |
| gptkbp:has_technology |
Data Analytics Tools
Biomarker Development Clinical Trial Management Systems Drug Discovery Technologies Laboratory Automation Systems |
| https://www.w3.org/2000/01/rdf-schema#label |
Lilly Research Laboratories
|
| gptkbp:known_for |
Drug Development
|
| gptkbp:located_in |
gptkb:Indianapolis,_Indiana
|
| gptkbp:moral |
Compliance with Regulations
Patient Safety Transparency in Research Research Integrity Responsible Research Practices |
| gptkbp:part_of |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:bfsParent |
gptkb:Eli_Lilly
|
| gptkbp:bfsLayer |
4
|